Kornimate/medical-research-clean huggingface dataset:
women's quality of life, sexual life and psychological state in patients undergoing embryo transfers

Conditions: Infertility, Female; Anxiety State; Depression; Quality of Life; Sexual Function and Fertility Disorders

Summary: women's quality of life, sexual life and psychological state would affect the success of embryo transfer. the primary purpose of the study is to compare women's quality of life, sexual life and psychological state using validated forms between those undergoing fresh embryo transfer and those undergoing frozen embryo transfer.

there are two types of embryo transfers; fresh and frozen embryo transfers. studies have been conducted to compare success rates between fresh and frozen embryo transfers. however, most studies have not taken into consideration women's quality of life, sexual life and psychological state in comparing fresh embryo transfer with frozen embryo transfers. these all parameters are confounding factors that may influence the success of embryo transfer. the purpose of this study is to compare women's quality of life, sexual life and psychological state using validated forms between those undergoing fresh embryo transfer and those undergoing frozen embryo transfer. the following forms will be used: expanded version of the inventory of depression and anxiety symptoms (idas-ii), beck anxiety inventory (bai), short form survey (sf-36) and female sexual function index (fsfi. this study can provide evidence regarding the association between women's quality of life, sexual life and psychological state and embryo transfer success.

Eligibility criteria:
inclusion criteria: * age between 20 - 39 years * body mass index between 18 -3 5 kg/m2 * anti-mullerian hormone levele \>1.1 ng/ml or antral follicle count \> 8 * fresh or frozen embryo transfer using middle-quality or good-quality day 3 or 5 embryos exclusion criteria: * age below 20 or over 39 years * uterine malformations * hypo or hyperthyroidism * diabetes mellitus * previous history of psychiatric disorders * use of psychiatric medications * systemic disorders (hypertension, chronic liver/kidney/heart problems)
assessment of the effects of sheffield support snood in mnd patients

Conditions: Motor Neurone Disease

Summary: the aim of this study is to evaluate the effects on mnd patients of a new collar specifically designed for people affected by neck weakness: the sheffield support snood.

motor neurone disease (mnd) is neurodegenerative disorder that leads to progressive weakness of limb, bulbar and respiratory muscles. the most common form of the disease is the amyotrophic lateral sclerosis (als). severe weakness of the neck extensor muscles is common in patients with als. those patients are advised to wear a cervical collar, to improve their neck posture and social interaction. however the main limit of commercially available collars is that they are designed to immobilize the neck, which makes them uncomfortable and strenuous to wear for long time. the aim of this study is to evaluate the effects on mnd patients of a new collar specifically designed for people affected by neck weakness: the sheffield support snood. the assessment will be performed through the use of inertial sensors since they allow the measurement to be performed in real life settings (clinics/home) with reduced discomfort to the patient. subjects will be asked to perform a series of active head movements (flexion, extension, axial rotation, lateral bending) with and without the collar and the range of movement measured in the two cases will be used to assess the support offered by the collar. since in mnd patients difficulty in perform active head movements is due to a severe weakness of the extensor muscles, with or without involvement of the neck flexors, this study will also investigate the activation of these muscles while the subject is performing the active head movements. a wireless surface electromyographic system (semg) will be used to this purpose. patients able to perform a series of activities of daily living (adl, ie: drinking, eating, washing hands) will be asked to perform the tasks both with and without the collar. the support perceived by the subjects while they are performing the adl will be evaluated through a questionnaire specifically developed for this study.

Eligibility criteria:
inclusion criteria: * clinical status consistent with mnd * capability to understand instructions * capability to perform testing procedures * ability to give informed consent exclusion criteria: * presence of any inflammatory or other disease involving joint or muscle pathology that might affects testing results * unable to give informed consent
acupuncture for rhinitis complicated with asthma

Conditions: Allergic Rhinitis; Asthma

Summary: this randomized controlled study aimed to evaluate the efficacy and safety of acupuncture therapy on persistent allergic rhinitis patients complicated with asthma.


Eligibility criteria:
inclusion criteria: 1. suffering from persistent allergic rhinitis (par; nasal obstruction, rhinorrhoea, sneezing and nasal itching) symptoms for more than 4 days/week, and greater than 4 consecutive weeks. 2. moderate-severe symptoms according to allergic rhinitis and its impact on asthma (aria) criteria. 3. positive reaction for more than or equal to one respiratory allergen (spt or mast) 4. stable asthma symptoms with diagnosis of asthma by respiratory or allergic disease specialist. 5. no changes in asthma or allergic rhinitis drugs for the past month 6. aged greater than or equal to 18 years, either sex. 7. no problem with expression of opinion 8. provided with written consent 9. no other disease except allergic rhinitis or asthma which could affect the disease. exclusion criteria: 1. having experience using ventilator due to exacerbation of asthma symptoms within six months. 2. experience of acute respiratory tract infection treated with antibiotics within 14 days 3. having anatomical occlusion or deformation in nasal cavity. 4. signs of infection in chest x-ray or having active respiratory disease except asthma 5. below or equal to 4 on total nasal symptom score (tnss) in the latest week. 6. received drugs affecting directly to allergic rhinitis such as h1-antihistamines, decongestants (nasal, oral or ocular), corticosteroids within 14 days. 7. received following treatments for allergic rhinitis or asthma within six months ; traditional korean medicine interventions such as acupuncture, moxibustion, cupping therapy and herbal medication inhalation or cam including homeopathy. 8. received herbal medication for allergic rhinitis or asthma within 14 days. 9. pregnant, planning the pregnancy or breast-feeding 10. tuberculosis, hepatitis or more than 2 x normal limit of serum creatinine, aspartate aminotransferase/alanine aminotransferase (ast/alt). 11. skin lesion on acupoint or other systemic disease insufficient for acupuncture. 12. night-shift workers staying up all night 13. who cannot participate clinical trial properly.
simultaneous quantification of liver fat content, fatty acid composition, and fibrosis using spin-lock mri for steatohepatitis assessment

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD); Non-alcoholic Steatohepatitis (NASH)

Summary: non-alcoholic fatty liver disease is a major health problem worldwide. it includes simple steatosis and nash which has inflammation in the liver, with or without fibrosis. fat content, fibrosis, and inflammation are three important components to evaluate nash. liver biopsy is the current gold standard for the diagnosis of nash. liver biopsy; however, is invasive. the existing non-invasive methods still have significant limitations to assess nash. it was reported that quantification of fatty acid composition is feasible for evaluation of metabolic disorders and inflammatory conditions. however, this measurement cannot be used to evaluate fibrosis. liver fibrosis is characterized by excessive deposition of collagen-rich connective tissues in the liver, which can be quantified by macromolecular proton fraction (mpf), an mri parameter reflecting the macromolecular level in tissues. although it has the potential to directly quantify fibrotic tissue, the effect of inflammation on mpf measurement was not well studied. in summary, nash assessment using non-invasive imaging methods remains challenging. based on our previous work of mpf imaging with spin-lock (mpf-sl) and chemical-shift encoding-based water-fat imaging in spin-lock mri, the investigators will develop a fast acquisition technology to collect data for simultaneous quantification of liver fat content, fatty acid composition, and fibrosis within a single breath-hold less than 14 seconds. our method does not require extra hardware and does not need to inject a contrast agent. the investigators will evaluate the repeatability and reproducibility of the proposed method on volunteers. to evaluate its clinical value, the investigators will recruit 120 subjects (60 with simple steatosis and 60 with nash) in this study. the investigators will use histology analysis as the gold standard and evaluate the diagnostic value of our proposed method for detecting nash. this project will provide a non-invasive diagnostic technology for the assessment of nash. the proposed mri technology also has the potential to be applied for other clinical purposes.


Eligibility criteria:
inclusion criteria: * between 18 and 65 years of age. * non-alcoholic fatty liver disease (nafld) patients at stage of either non-alcoholic steatohepatitis (nash) or simple steatosis * nafld patients scheduled to undergo liver biopsy. * no abnormal lesions detected at baseline mri exam for healthy volunteers. exclusion criteria: * evidence of hepatocarcinoma (hcc) or any other types of neoplasm. * patients who had undergone liver transplantation. * any contraindications to either liver biopsy or mri scan.

Keywords: chronic liver diseases liver fibrosis fatty acid spin-lock mri non-invasive imaging
individualization of ovarian stimulation using amh maximizes the benefits and minimizes complications and risks

Conditions: Infertility

Summary: the purpose oh the study is to determine the usefulness of anti-mullerian hormone (amh) to identify women at risk of excessive and poor response in controlled ovarian stimulation (cos) for in vitro fertilization (ivf), and the clinical impact of applying individualized cos strategies in these subsets of patients.

a group of 130 women undergoing conventional cos after pituitary down-regulation for ivf will be studied to determine the best cut-off points of amh, using receiver operating characteristic (roc) analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved). the inclusion criteria is any patient with indication of ivf treatment. subsequently, a different group of 120 women (with the same criteria) will be assessed using amh before starting cos, and treatment strategy will be individualized according to amh results (icos). mild stimulation using daily doses (112.5 to 150 iu) of recombinant follicle stimulation hormone (rec-hfsh) or rec-hfsh combined with recombinant luteinizing hormone (lh) supplementation (375 iu total daily dose) will be given to patients identified as at risk of excessive and poor response, respectively. it will evaluated: number of oocytes, clinical pregnancy rates (defined as fetal heartbeat on ultrasound performed 4 weeks after the transfer of embryos) and occurrence of ovarian hyperstimulation syndrome). outcomes will be compared between the groups who received conventional and icos using chi-square and fisher exact tests.

Eligibility criteria:
inclusion criteria: * women with in vitro fertilization treatment indication exclusion criteria: * none

Keywords: in vitro fertilization ovulation induction anti-mullerian hormone
myelodysplasic syndromes and risk factors for infection

Conditions: Myelodysplastic Syndrome (MDS); Infection; Risk Factors; IPSS High Risk

Summary: myelodysplastic syndromes (mds) are characterized by quantitative and qualitative bone marrow failure and by a disorder of the medullary production which is a pre-leukemic state which can evolve into acute myeloid leukemia. the risk of leukemic transformation is estimated by the score ipss (international prognostic score system). we distinguish the mds of low risk (ipss\<1) and those of high risk of leukemic transformation (ipss=1,5). besides the risk of leukemic transformation, mds much be complicated of infections which could be life-threatening. the risk of developing first infection after the diagnosis of mds of high risk is probably influenced by anamnestic (disease duration, comorbidities), clinical (veinous central catheter, previous hospitalization), biological (neutropenia, lymphopenia, serum ferritin) and therapeutics (demethylating agent, lenalidomide, erythropoietin, g-csf, transfusions, anti-infectious preventive treatment) factors. their identification will allow for improved targeting of the population which is is likely to benefit from anti-infective prophylaxis primary objective is to identify risk factors associated with first acute episode of infection in patients with mds, by comparing index cases and matched control cases who did not develop infection episode since diagnosis. secondary objectives are to explore nature and severity of infectious episodes, number of recurrences during 1 year of follow up and survival at 6 and 12 months

* 160 couples (case / control) * pairing according to age (+/- 5 years), sex and medical consultation date (+/-15 days) * follow up at m3, m6, m9 and m12 * study duration : 24 months * inclusion duration : 12 months

Eligibility criteria:
inclusion criteria: * age \> 18 years old * mds with ipss \>1.5 * with a first infectious episode since the diagnosis of smd of high risk (case) * unhurt of any infection and being able to be mated in the case index (control) * consulting or hospitalized in one of the services involved in the study during the period of inclusion exclusion criteria: * none

Keywords: myelodysplastic syndrome (myelodysplasia) infection risk factors
non-invasive determination of fetal chromosome abnormalities

Conditions: Down Syndrome (Trisomy 21); Edward's Syndrome (Trisomy 18); Patau Syndrome (Trisomy 13); Klinefelter Syndrome (47, XXY); and Other Chromosome; Abnormalities.

Summary: the overall significance of this study is to develop a laboratory developed test (ldt) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as down syndrome (trisomy 21), edward's syndrome (trisomy 18), patau syndrome (trisomy 13), klinefelter syndrome, (47, xxy), and other chromosome abnormalities. accomplishing that task would reduce the need for invasive amniocentesis and cvs procedures.


Eligibility criteria:
inclusion criteria: * this study is only applicable to women who are between 8 and 30 weeks' gestation and who have been determined increased risk for fetal aneuploidy. in the interest of expediting and simplifying this study, the investigators want only women who have already decided to undergo second-trimester amniocentesis or cvs. exclusion criteria: * the only exclusion criteria are those mentioned.
effect of a nutritional supplement on h&n cancer patients

Conditions: Head and Neck Cancer

Summary: to determine if using a nutritionally enhanced supplement will improve mucositis in head and neck cancer patients

h\&n cancer patients will be randomized to receive either a nutritionally enhanced product or standard treatment. the patients in both groups will receive nutritional counseling weekly by the rd. anthropometric measures, available lab values, mucositis grade, and quality of life measures will be compared between groups.

Eligibility criteria:
inclusion criteria: * head and neck cancer 1st.2nd wk rx read \&wrte eng exclusion criteria: * receiving hospice impaired cognition

Keywords: cancer nutrition
study to find the percentage of cases retaining covid-19 igg antibodies 45-65 after they have tested positive

Conditions: Covid19

Summary: as a serosurveillance measure asymptomatic employees of an industrial workforce jamshedpur (india) were tested for covid-19 igg antibodies. of the tested employees who were positive for covid-19 igg antibodies the study aimed to find the percentage of cases who retained their covid-19 igg antibodies 45-65 days after initially testing positive.

as a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce jamshedpur (india) were tested for covid-19 igg antibodies specific for the spike subunit antigen by the erbalisa covid-19, erba corporate services (united kingdom) between 28th june and 15th july 2020. the cases who tested positive for covid-19 igg antibodies were repeat tested for the presence of covid-19 igg at 45-65 days after initially testing positive. this was done with the aim of finding out the percentage of cases retaining their igg antibodies at 45-65 days of initially testing positive.

Eligibility criteria:
inclusion criteria: sars-cov-2 igg antibody positive between 28th june and 15th july 2020 exclusion criteria: sars-cov-2 igg antibody negative between 28th june and 15th july 2020
wtx212a monotherapy and in combination with pd -1/pd-l1 monoclonal antibody

Conditions: Advanced Lung Cancer

Summary: this trial is a single-center, open-label designed investigator-initiated clinical study (iit) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of wtx212a injection wtx212a injection combined with pd -1/pd-l1 monoclonal antibody in patients with advanced lung cancer

the trial consist of screening period (30 days), treatment period (21\*n days), safety follow-up period (90 days) and survival follow-up. about 20 subjects are planned to be enrolled in the study.

Eligibility criteria:
inclusion criteria: * the subject signs an informed consent form, understands this study, is willing to follow and has the ability to complete all experimental procedures; * regardless of gender, aged 18 to 75 years old (including threshold); * histologically or cytologically confirmed locally advanced (stage iib/iic) or metastatic (stage iv) non-small cell lung cancer (nsclc) with disease progression or intolerance after treatment or extensive stage small cell lung cancer (sclc) * patients with lung cancer who have been treated with at least 1 line system therapy or cannot currently receive standard therapy, and who have been treated with pd-1 or pd-l1 inhibitor antibody in the terminal line therapy regimen for ≥ 2 cycles; * ecog ≤1 * expected life ≥ 3 months； * male participants, their spouses, and female participants of childbearing age should agree to use a medically recognized effective contraceptive method from the signing of the informed consent form until 3 months after the last administration; exclusion criteria: * people with other serious medical diseases, including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc., and people with uncontrollable or serious cardiovascular diseases, * patients with clinical symptoms and the need for repeated drainage of pleural and ascitic fluids; * previous or recent history of pulmonary fibrosis, severe lung function damage caused by pneumoconiosis, radiation pneumonia, and drug-related pneumonia; * there have been adverse events related to the use of io drugs that require permanent cessation of io treatment; * known to have other malignant tumors, currently progressing or completing treatment at least once in the past 3 years. exceptions include early tumors that have received radical treatment (carcinoma in situ or grade 1 tumor, non ulcerative primary melanoma with a depth of less than 1mm and no lymph nodes involved), skin basal cell carcinoma, skin squamous cell carcinoma, cervical carcinoma in situ, or breast carcinoma in situ that has received potential radical treatment; * subjects with symptomatic central nervous system (cns) metastasis confirmed by imaging or pathological examination and clinically unstable for at least 14 days prior to enrollment who require steroid treatment; * having hereditary bleeding tendencies or coagulation disorders, or a history of thrombosis, hemolysis, or hemorrhagic diseases; * received significant surgical treatment or obvious traumatic injury within 28 days prior to the start of research treatment;
uterine evaluation for the identification of pathology. this study will compare the intrauterine pathology detection rate between standard of care hydrosonography, and a new visual saline infusion device providing direct visualization of the uterus.

Conditions: Hysteroscopy; Hysteroscopy Technique; Fertility Issues; Uterus Abnormal; Gynecology; Visualization; Infertility Female

Summary: this is a prospective, single center, multiple arm cohort study intended to compare the diagnostic accuracy of a visual saline infusion device (vsi) device, vs standard of care hydrosonography in reproductive aged women to identify pathology in the uterus.

this is a prospective, single center, multiple arm cohort study intended to compare the diagnostic accuracy of a visual saline infusion device (vsi) device, vs standard of care hydrosonography in reproductive aged women to identify pathology in the uterus. patients who are enrolled in the study will have a 1) hydrosonography, and 2) visual saline infusion procedure performed. the visual saline infusion device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. the device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's). this study will recruit up to 100 women from a fertility center in los angeles.

Eligibility criteria:
inclusion criteria: 1. patients requiring a uterine cavity evaluation 2. premenopausal women between ages of 18-45 exclusion criteria: 1. positive test or history of any of the following conditions: 1a. chlamydial pelvic infection 1b. gonorrheal pelvic infection. 2. positive pregnancy test 3. iud currently in place

Keywords: hysteroscopy fertility gynecology hydrosonography uterine evaluation uterine pathology
effect of clomiphene citrate on uterine blood fow in women with unexplained delayed conception

Conditions: Infertility, Female

Summary: in a prospective observational study at a university teaching hospital, blood flow indices and serum hormone levels were compared between spontaneous and stimulated cycles in the same group of 50 patients with unexplained delayed conception.

in a prospective observational study at a university teaching hospital, the mid-luteal (peri-implantation) endometrial thickness and volume, uterine artery pulsatility index (pi) and resistance index (ri), endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were compared between spontaneous and clomiphene citrate stimulated cycles in the same group of 50 patients with unexplained infertility.

Eligibility criteria:
inclusion criteria: * unexplained infertility * body mass index less than 30 * regular menstruation * normal pelvic examination and ultrasonography exclusion criteria: * history of pelvic operations including cesarean section * history of pelvic inflammatory disease * endometriosis * pelvic pathology including uterine fibroids * general disease or medication that could potentially affect pelvic blood flow * smoking